{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:46:06Z","timestamp":1789969566905,"version":"4.0.1"},"reference-count":73,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T00:00:00Z","timestamp":1365120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p>\n                    The Kv1.3 and\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 potassium channels are promising targets for the treatment of autoimmune disorders. Many\n                    <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                    v1.3 and\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockers have a more favorable adverse event profiles than existing immunosuppressants, suggesting the selectivity of\n                    <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                    v1.3 and\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockade. The\n                    <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                    v1.3 and\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockers exert differential effects in different autoimmune diseases. The Kv1.3 inhibitors or gene deletion have been shown to have benefits in multiple sclerosis, type 1 diabetes, rheumatoid arthritis, psoriasis, and rapidly progressive glomerulonephritis. The\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockers have demonstrated efficacy in human primary biliary cirrhosis and showed protective effects in animal models of severe colitis, allergic encephalomyelitis, inflammatory bowel disease, and multiple sclerosis. The\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockers are not considered candidates for treatment of multiple sclerosis. The selective immunosuppressive effects of the Kv1.3 and\n                    <jats:styled-content style=\"fixed-case\">\n                      K\n                      <jats:sub>C<\/jats:sub>\n                    <\/jats:styled-content>\n                    <jats:sub>a<\/jats:sub>\n                    3.1 blockers are due to the differences in their distribution on autoimmune\u2013related immune cells and tissues and \u03b21 integrin (very late activating antigen)\u2013\n                    <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                    v1.3 channel cross\u2010talk.\n                  <\/jats:p>","DOI":"10.1002\/phar.1236","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T14:42:39Z","timestamp":1365172959000},"page":"515-528","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting Potassium Channels\n                    <scp>K<\/scp>\n                    v1.3 and\n                    <scp>\n                      K\n                      <sub>C<\/sub>\n                    <\/scp>\n                    <sub>a<\/sub>\n                    3.1: Routes to Selective Immunomodulators in Autoimmune Disorder Treatment?"],"prefix":"10.1002","volume":"33","author":[{"given":"Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacology School of Pharmacy Tongji Medical College Huazhong University of Science and Technology Wuhan China"},{"name":"Department of Pharmacology College of Medicine Wuhan University of Science and Technology Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology School of Pharmacy Tongji Medical College Huazhong University of Science and Technology Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr078234p"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2007.01.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501770102"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.245"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2012.04.023"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8283-x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526078"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/80516"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605136103"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00362.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20467"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2012.05.013"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003941200"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.03.010"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152811797200641"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2011.07.016"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.052704"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802054200"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910133107"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2010.06.009"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.7.1167"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00374.2010"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.65.6.1364"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.015669"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2008.10.033"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6807-11-3"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21522"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2009.11.001"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425954"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02143.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.379594"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2010.532886"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M706008200"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.776"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.025"},{"key":"e_1_2_6_37_1","first-page":"438","article-title":"Targeting effector memory T\u2010cells with Kv1.3 blockers","volume":"10","author":"Wulff H","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.07.015"},{"key":"e_1_2_6_39_1","first-page":"1896","article-title":"Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4\u00a0+\u00a0 T lymphocytes in multiple sclerosis","volume":"88","author":"Ren XT","year":"2008","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00816.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191890"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.008193"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700717"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004009"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304879200"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16921"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.3181\/0705-RM-148"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.296798"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241497298"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103095"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212868200"},{"key":"e_1_2_6_52_1","first-page":"640","article-title":"Potassium channels as therapeutic targets for autoimmune disorders","volume":"6","author":"Wulff H","year":"2003","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2009.04.008"},{"key":"e_1_2_6_54_1","first-page":"1434","article-title":"The voltage\u2010gated potassium channel Kv1.3 in psoriasis and psoriatic arthritis: a therapeutic target for T cell\u2010mediated autoimmune diseases","volume":"60","author":"Raychaudhuri SP","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2994"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.161"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107507200"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2548"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-8-3"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707780831186"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1108163"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.3.1442"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.3.1153"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.12.8040"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02161.x"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.060319"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200637024"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200738106"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.07.009"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00147"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0904-2"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.57.4.10"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2009.12.015"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00223.2009"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1236","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:10:38Z","timestamp":1761070238000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1002\/phar.1236"],"URL":"https:\/\/doi.org\/10.1002\/phar.1236","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,5]]},"assertion":[{"value":"2013-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}